Phase III trial of Libtayo as monotherapy for first-line advanced NSCLC stopped early due to highly significant improvement in overall survival.- Sanofi + Regeneron
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest